A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Purpose
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Conditions
- Atopic Dermatitis
- Alopecia Areata
- Hidradenitis Suppurativa
- Vitiligo
- Psoriasis
- Chronic Spontaneous Urticaria
Eligibility
- Eligible Ages
- All ages
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment. - 2. Participant has plans for future visits at the site for continued management of IMISC.
Exclusion Criteria
- 1. Inability to provide written informed consent/assent. - 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Other
Recruiting Locations
Fort Smith 4111410, Arkansas 4099753 72916
Little Rock 4119403, Arkansas 4099753 72223
Fountain Valley 5350207, California 5332921 92708
San Diego 5391811, California 5332921 92123
Washington D.C. 4140963, District of Columbia 4138106 20037
Chicago 4887398, Illinois 4896861 60611
Indianapolis 4259418, Indiana 4921868 46520
Kansas City 4273837, Kansas 4273857 66160
Rockville 4367175, Maryland 4361885 20850
Minneapolis 5037649, Minnesota 5037779 55455
Lebanon 5088597, New Hampshire 5090174 03756
East Windsor 8354649, New Jersey 5101760 08520
Brooklyn 5110302, New York 5128638 11219
East Syracuse 5116079, New York 5128638 13057
New York 5128581, New York 5128638 10012
New York 5128581, New York 5128638 10029
Asheville 4453066, North Carolina 4482348 28801
Winston-Salem 4499612, North Carolina 4482348 27157
Columbus 4509177, Ohio 5165418 43215
Portland 5746545, Oregon 5744337 97239
Pittsburgh 5206379, Pennsylvania 6254927 15241
Charleston 4574324, South Carolina 4597040 29425
El Paso 5520993, Texas 4736286 79902
Murray 5778755, Utah 5549030 84107
Murray 5778755, Utah 5549030 84107
Mill Creek 5803457, Washington 5815135 98012
More Details
- NCT ID
- NCT03661866
- Status
- Recruiting
- Sponsor
- Target PharmaSolutions, Inc.
Detailed Description
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies. The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.